Cargando…

JAK Inhibitors and Oxidative Stress Control

Primary Sjögren's syndrome (SjS) is a complex autoimmune epithelitis, with few treatment options, but the use of Janus kinase (JAK) inhibitors is promising because suppression of the JAK/signal transducer and activator of transcription (STAT) pathway improves sicca manifestations. Playing a pri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charras, Amandine, Arvaniti, Pinelopi, Le Dantec, Christelle, Dalekos, George N., Zachou, Kaliopi, Bordron, Anne, Renaudineau, Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908489/ https://www.ncbi.nlm.nih.gov/pubmed/31867003 http://dx.doi.org/10.3389/fimmu.2019.02814

Ejemplares similares

An in silico Approach Reveals Associations between Genetic and Epigenetic Factors within Regulatory Elements in B Cells from Primary Sjögren’s Syndrome Patients
por: Konsta, Orsia D., et al.
Publicado: (2015)

Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren’s Syndrome and Primary Biliary Cholangitis
por: Arvaniti, Pinelopi, et al.
Publicado: (2019)

First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients
por: Dalekos, George N., et al.
Publicado: (2022)

Impact of genetic and environmental factors on autoimmune hepatitis
por: Zachou, Kalliopi, et al.
Publicado: (2021)

Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis
por: Arvaniti, Pinelopi, et al.
Publicado: (2018)

Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
por: Arvaniti, Pinelopi, et al.
Publicado: (2020)

Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?
por: Zachou, Kalliopi, et al.
Publicado: (2017)

Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion
por: Bagacean, Cristina, et al.
Publicado: (2017)

Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia
por: Doumtsis, Petros, et al.
Publicado: (2018)

Acute non-A, non-B, non-C hepatitis differences and similarities between hepatitis E virus infection and autoimmune hepatitis, with phylogenetic analysis of hepatitis E virus in humans and wild boars
por: Zachou, Kalliopi, et al.
Publicado: (2022)

Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis
por: Dalekos, George N., et al.
Publicado: (2022)

FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease
por: Arvaniti, Pinelopi, et al.
Publicado: (2023)

Human Endogenous Retrovirus Group E and Its Involvement in Diseases
por: Le Dantec, Christelle, et al.
Publicado: (2015)

Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2017)

DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag
por: Bagacean, Cristina, et al.
Publicado: (2017)

Emerging Topical and Systemic JAK Inhibitors in Dermatology
por: Solimani, Farzan, et al.
Publicado: (2019)

Perspectives of JAK Inhibitors for Large Vessel Vasculitis
por: Watanabe, Ryu, et al.
Publicado: (2022)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

The contribution of epigenetics in Sjögren’s Syndrome
por: Konsta, Orsia D., et al.
Publicado: (2014)

Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease
por: Zachou, Kalliopi, et al.
Publicado: (2004)

Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity
por: Hadjadj, Jérôme, et al.
Publicado: (2021)

Metabolic Program of Regulatory B Lymphocytes and Influence in the Control of Malignant and Autoimmune Situations
por: Iperi, Cristian, et al.
Publicado: (2021)

Early Primary Biliary Cirrhosis: A New Association with Erythema Nodosum of Unknown Origin
por: Gatselis, Nikolaos K., et al.
Publicado: (2010)

Editorial: Role of Macrophage MicroRNAs in Inflammatory Diseases and Cancer
por: Renaudineau, Yves, et al.
Publicado: (2021)

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Deciphering the maturation of tertiary lymphoid structures in cancer and inflammatory diseases of the digestive tract using imaging mass cytometry
por: Le Rochais, Marion, et al.
Publicado: (2023)

JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis
por: Frede, Natalie, et al.
Publicado: (2023)

Management of Patients with Liver Cirrhosis and Invasive Bladder Cancer: A Case-series
por: Zachos, Ioannis, et al.
Publicado: (2019)

An Immunocompetent HIV-Negative Elderly Patient with Low-Grade Fever, Generalized Lymphadenopathy, Splenomegaly, and Acute Phase Response: Do Not Forget Castleman Disease
por: Azariadis, Kalliopi, et al.
Publicado: (2021)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

DNA methylation patterns in CD4(+) T-cells separate psoriasis patients from healthy controls, and skin psoriasis from psoriatic arthritis
por: Natoli, Valentina, et al.
Publicado: (2023)

Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
por: Wei, Dongfan, et al.
Publicado: (2023)

Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants
por: Chen, Kan, et al.
Publicado: (2023)

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Associations between Viral Infection History Symptoms, Granulocyte Reactive Oxygen Species Activity, and Active Rheumatoid Arthritis Disease in Untreated Women at Onset: Results from a Longitudinal Cohort Study of Tatarstan Women
por: Arleevskaya, Marina I., et al.
Publicado: (2017)

Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials
por: Tasoudis, Panagiotis T., et al.
Publicado: (2022)

Severe Pharyngodynia Followed by Migratory Polyarthritis and High Fever in Young Immigrants: Remember That Rheumatic Fever Is Still Relevant in 2020!
por: Azariadis, Kalliopi, et al.
Publicado: (2020)

Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation
por: Niu, Guo-Juan, et al.
Publicado: (2018)

The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency
por: de Armas, Lesley R., et al.
Publicado: (2021)

Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections
por: Reece, Monica D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gqn4diuk5plniro2gmrfilqubh